Sera Prognostics to Showcase PreTRM Test at TD Cowen Health Care Conference
Event summary
- Sera Prognostics will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026.
- Management will participate in a fireside chat highlighting recent achievements.
- The company's PreTRM Test is the only broadly validated blood-based biomarker test for predicting preterm birth.
- Preterm birth costs the U.S. healthcare system approximately $25 billion annually.
The big picture
Sera Prognostics' participation in the TD Cowen Health Care Conference underscores its strategic focus on expanding investor awareness and market penetration for its PreTRM Test. The test addresses a significant unmet need in maternal health, given the persistent high rates of preterm birth in the U.S. and the associated healthcare costs. The company's ability to secure broader adoption and reimbursement will be critical to its long-term success.
What we're watching
- Market Adoption
- Whether Sera Prognostics can achieve broad scientific and market acceptance of the PreTRM Test.
- Reimbursement Dynamics
- The pace at which third-party payer coverage and reimbursement methodologies evolve for the PreTRM Test.
- Competitive Positioning
- How Sera Prognostics will differentiate itself in a potentially competitive landscape for pregnancy biomarker tests.
Related topics